Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tumor cell apoptosis pathway (lectin-induced) is a mechanism by which lectins, carbohydrate-binding proteins, induce programmed cell death in cancer cells. This process leverages altered glycosylation patterns on tumor cells, allowing lectins to selectively bind and trigger apoptosis through intrinsic and extrinsic pathways involving caspases, BCL2 family proteins, and potentially autophagy. Selectivity and resistance are key considerations for therapeutic applications.
Lectins bind to tumor-associated carbohydrate antigens (TACAs) on cancer cells, triggering apoptosis through intrinsic (mitochondrial) and extrinsic (death receptor) pathways. This involves caspase activation, BCL2 family protein modulation, and potential autophagic cell death.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Cell Apoptosis Pathway (Lectin-Induced).